June 24, 2025 — On the closing day of the ADA Scientific Sessions in Chicago, we got a good look at two remarkable new obesity drugs. Both of them have potential to bring important advances. Both of them need more work before they will be ready to go to FDA for approval. This was a rare treat. Bimagrumab The […]
October 4, 2023 — People have “lots of interest” in the effects of GLP-1 treatment for obesity on body composition, reports endocrinologist Daniel Drucker from EASD in Hamburg. Judging from clickbait headlines about semaglutide, we suspect public interest in this question is strong as well. So that makes data presented at EASD from the SURPASS study on muscle composition […]
July 20, 2023 — Obesity care is suffering from a blinding distraction – BMI and weight loss. It’s not hard to find critiques of this. The American Medical Association recently cautioned physicians against the misuse of BMI as a surrogate for health and obesity. PLOS One has a new paper telling us BMI may not necessarily increase mortality independently […]
January 6, 2020 — It was a stunning and unique result that seemed to come out of nowhere at ObesityWeek late last year. A new drug, bimagrumab, yielded a 21 percent reduction in fat mass after 48 weeks. But lean body mass went up by 3.6 percent. This result is distinctly different from what usually happens in obesity treatment. […]
